Sinocelltech Group Ltd Cash Flow Conversion Efficiency
Sinocelltech Group Ltd cash flow conversion efficiency. Based on the latest financial reports, Sinocelltech Group Ltd (688520) has a cash flow conversion efficiency ratio of 0.137x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-100.18 Million ≈ $-14.66 Million USD) by net assets (CN¥-730.66 Million ≈ $-106.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sinocelltech Group Ltd (2016–2024)
Cash flow conversion efficiency of Sinocelltech Group Ltd from 2016 to 2024. This chart illustrates how Sinocelltech Group Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Sinocelltech Group Ltd for real-time trading data and today's change.
Sinocelltech Group Ltd Cash Flow Conversion Ratio Explained
Sinocelltech Group Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sinocelltech Group Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sinocelltech Group Ltd ranked by their cash flow conversion efficiency. Also see market value of Sinocelltech Group Ltd for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Y.H. Dimri Construction & Development Ltd
TA:DIMRI
|
-0.148x |
|
Skyward Specialty Insurance Group, Inc. Common Stock
NASDAQ:SKWD
|
0.042x |
|
Zhejiang Weixing New Building Materials Co Ltd
SHE:002372
|
0.075x |
|
Dno ASA
OL:DNO
|
0.225x |
|
Shanghai Zhenhua Heavy Industries Co Ltd A
SHG:600320
|
-0.034x |
|
Altius Minerals Corporation
TO:ALS
|
-0.003x |
|
Formula Systems 1985 Ltd ADR
NASDAQ:FORTY
|
0.009x |
|
McGraw Hill, Inc.
NYSE:MH
|
-0.201x |
Annual Cash Flow Conversion Efficiency for Sinocelltech Group Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Sinocelltech Group Ltd from 2016 to 2024. Review 688520 free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥134.94 Million ≈ $19.75 Million |
CN¥125.12 Million ≈ $18.31 Million |
0.927x | +47.52% |
| 2023-12-31 | CN¥-605.81 Million ≈ $-88.65 Million |
CN¥-380.80 Million ≈ $-55.72 Million |
0.629x | -64.42% |
| 2022-12-31 | CN¥-242.19 Million ≈ $-35.44 Million |
CN¥-427.91 Million ≈ $-62.62 Million |
1.767x | -52.70% |
| 2021-12-31 | CN¥-230.99 Million ≈ $-33.80 Million |
CN¥-862.82 Million ≈ $-126.26 Million |
3.735x | +508.95% |
| 2020-12-31 | CN¥588.36 Million ≈ $86.10 Million |
CN¥-537.41 Million ≈ $-78.64 Million |
-0.913x | +93.45% |
| 2019-12-31 | CN¥34.80 Million ≈ $5.09 Million |
CN¥-485.10 Million ≈ $-70.99 Million |
-13.938x | -477.54% |
| 2018-12-31 | CN¥-23.84 Million ≈ $-3.49 Million |
CN¥-88.02 Million ≈ $-12.88 Million |
3.692x | +764.28% |
| 2017-12-31 | CN¥167.84 Million ≈ $24.56 Million |
CN¥-93.28 Million ≈ $-13.65 Million |
-0.556x | -10.91% |
| 2016-12-31 | CN¥80.38 Million ≈ $11.76 Million |
CN¥-40.28 Million ≈ $-5.89 Million |
-0.501x | -- |
About Sinocelltech Group Ltd
Sinocelltech Group Limited, a biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, and vaccines in China. The company offers Anjiayin, a third-generation recombinant coagulation factor VIII product for the treatment of hemophilia A; Anpingxi, an anti-CD20 monoclonal antibody for the treatment of CD20-positive diffuse large B-cell… Read more